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Abstract
Background: Research into methods to boost recruitment has been identified as the highest priority for
randomised controlled trial (RCT) methodological research in the United Kingdom. Slow recruitment delays the
delivery of research and inflates costs. Using electronic patient records has been shown to boost recruitment to
ongoing RCTs in primary care by identifying potentially eligible participants, but this approach remains relatively
unexplored in secondary care, and for stroke in particular.
Methods/design: The REstart or STop Antithrombotics Randomised Trial (RESTART; ISRCTN71907627) is an
ongoing RCT of secondary prevention after stroke due to intracerebral haemorrhage. Promoting Recruitment using
Information Management Efficiently (PRIME) is a stepped-wedge cluster randomised trial of a complex intervention
to help RESTART sites increase their recruitment and attain their own target numbers of participants. Seventy-two
hospital sites that were located in England, Wales or Scotland and were active in RESTART in June 2015 opted into
PRIME. Sites were randomly allocated (using a computer-generated block randomisation algorithm, stratified by
hospital location in Scotland vs. England/Wales) to one of 12 months in which the intervention would be delivered.
All sites began in the control state. The intervention was delivered by a recruitment co-ordinator via a teleconference
with each site. The intervention involved discussing recruitment strategies, providing software for each site to
extract from their own stroke audit data lists of patients who were potentially eligible for RESTART, and a second
teleconference to review progress 6 months later. The recruitment co-ordinator was blinded to the timing of
the intervention until 2 months before it was due at a site. Staff at RESTART sites were blinded to the nature
and timing of the intervention. The primary outcome is the total number of patients randomised into RESTART
per month per site and will be analysed in a negative binomial generalised linear mixed model. PRIME began
in September 2015. The last intervention was delivered in August 2016. Six-month follow-up will be complete in
February 2017.
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Discussion: The final results of PRIME will be analysed and disseminated in 2017.
Trial registration: The PRIME study was registered in the Northern Ireland Hub for Trials Methodology Research
Studies Within a Trial (SWAT) repository (SWAT22) on 23 December 2015.
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Background
Research into methods to boost recruitment into rando-
mised controlled trials (RCTs) is the highest priority for
trial methodological research. A Delphi survey of 48 UK
Clinical Research Collaboration-registered clinical trials
units achieved consensus, and it identified that the top
three priorities for trial methodological research were
‘Research into methods to boost recruitment in trials’
(considered the highest priority), ‘Methods to minimise
attrition’ and ‘Choosing appropriate outcomes to measure’
[1]. However, a systematic review concluded, ‘[T]here is a
clear knowledge gap with regard to effective strategies
aimed at recruiters’ ([2], pg 1).
The Lancet’s series ‘Research: Increasing Value and
Reducing Waste’ identified under-recruitment to RCTs as a
major source of inefficiency in the conduct of applied
clinical research [3]. Slow recruitment is particularly
inefficient because it delays the delivery of research and
inflates its costs by increasing the number of staff and sites
or by extending the amount and duration of funding
required. This problem has not been small; the authors of a
review of 114 RCTs funded by the Medical Research
Council (MRC) or the Health Technology Assessment
programme in the United Kingdom for the period 1994–
2002 found that less than one-third recruited their original
target within the time originally specified, and around
one-third were given extensions to achieve their target [4].
A marginal improvement was found when this review was
repeated for the period 2002–2008; almost half of the RCTs
did not recruit their originally specified target sample size,
and nearly half of the RCTs received an extension of
some kind [5]. Recruitment is jeopardised by many
factors, including restrictive eligibility criteria and in-
efficient methods for approaching participants [6, 7].
The REstart or STop Antithrombotics Randomised Trial
(RESTART [ISRCTN71907627]; http://www.restarttrial.org/)
is an ongoing RCT comparing starting vs. avoiding anti-
platelet drugs after stroke due to intracerebral haemorrhage
(ICH) whose aim was to recruit 720 participants over 2
years, with recruitment rates estimated using epidemio-
logical data [6, 8]. RESTART has implemented as many
as possible of the strategies that have been shown to
maximise recruitment [6, 9], and the chief investigator has
used qualitative methods with principal investigators (PIs)
at all active sites to identify and overcome barriers to clin-
ician recruitment activity [10]. However, by the end of 2
years of recruitment in May 2015, 108 hospital sites were
active in the United Kingdom and had recruited only 145
(20%) of the target number of participants in RESTART.
Because there is no upper time limit on patient recruit-
ment into RESTART after ICH onset, RESTART could
boost recruitment by recruiting prevalent patients. Using
electronic patient records has been shown to boost recruit-
ment to ongoing RCTs in primary care by identifying
potentially eligible participants [11, 12], but this approach
remains relatively unexplored in secondary care, and for
stroke in particular.
Therefore, we designed a stepped-wedge RCT embedded
within RESTART to investigate whether recruitment into
RESTART could be boosted by a complex intervention
involving investigators in secondary care using electronic
patient records held by national stroke audits. In this
article, we report version 1.0 of the Promoting Recruit-
ment using Information Management Efficiently (PRIME)
work instruction to hospital sites, which constitutes the
protocol for the trial.
Methods/design
Aims
The primary objective of the trial is to investigate if having
a recruitment co-ordinator who conducts a recruitment
review, provides access to bespoke stroke audit data
exports, and conducts a follow-up review after six months
improves the recruitment rate in RESTART at active
hospital sites in the RESTART collaboration. The second-
ary objectives are to investigate the following questions:
a. How many sites use routinely collected stroke audit
data (or other data sources) to identify potentially
eligible participants before the recruitment review?
b. How many sites use the bespoke stroke audit data
exports after the recruitment review, and how often?
c. What are the barriers to recruitment in general?
d. What are the barriers to using the bespoke stroke
audit data exports?
e. What are the disadvantages of using the bespoke
stroke audit data exports?
Design and setting
PRIME is a stepped-wedge cluster randomised trial
(within the RESTART parallel-group RCT) investigating
an intervention to boost recruitment in RESTART. At
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the time of inviting active hospital sites in RESTART to
take part in PRIME in June 2015, there were 109 active
hospital sites in the RESTART collaboration in the
United Kingdom. We excluded 24 sites including two
sites in Northern Ireland (where stroke audit data col-
lection was not consistent), two sites in Scotland and
two sites in England that piloted the PRIME interven-
tion. We also excluded sites that had been activated to
RESTART in 2015 to ensure that all sites taking part
had a number of months of recruitment before receiv-
ing the intervention. The PRIME recruitment co-
ordinator telephoned the RESTART co-ordinator at
each of the remaining 85 sites in ascending order of site
identification number to invite them to take part in a
‘recruitment review’, followed by an email if required,
until 72 sites agreed. Sites were not informed about the
exact content of the recruitment review or that its tim-
ing would be randomly allocated. The stepped-wedge
design involves sequential roll-out of the intervention
to clusters (active hospital sites in RESTART) over a
number of time periods [13]. The month in which clus-
ters start the intervention is randomly allocated so that
groups of clusters begin the intervention sequentially at
equally spaced time intervals (steps), and the outcome
of interest is measured following each step until after
all clusters have been allocated to the intervention
(Additional file 1: Figure S1). A cluster randomised
design was inevitable because the nature of the inter-
vention meant that it could not be applied at the par-
ticipant level. The stepped-wedge design is particularly
relevant where it is predicted that the intervention will
ultimately do more good than harm (making a parallel
design, in which some clusters do not receive the
intervention, potentially inefficient) and when the inter-
vention cannot practically be delivered to all sites
simultaneously. Because all clusters join the study at
the start and are expected to remain until study end,
the PRIME trial is an example of a closed cohort
stepped-wedge design [14].
Inclusion criteria
The inclusion criteria are as follows:
 Active RESTART site at the time of invitation for
the intervention
 Site participates in data collection for the national
stroke audits in Scotland or the rest of the United
Kingdom
 Site is in Scotland, England or Wales
Exclusion criteria
The exclusion criteria are as follows:
 Site participated in the PRIME pilot
 Site opted out when approached
Randomisation
A senior programmer at the Edinburgh Clinical Trials
Unit used a computer-generated block randomisation al-
gorithm to randomly allocate the 72 sites into 12 strata
of 6 sites each. Randomisation was stratified by hospital lo-
cation (Scotland vs. England/Wales) to ensure that the pro-
portions of sites with access to each national stroke audit
data source were approximately consistent across the 12
groups. All sites began in the control state. The order in
which the groups of sites step in to implement the
intervention was determined by the randomisation algo-
rithm. The randomisation list is held by the RESTART
data manager.
Blinding
The recruitment co-ordinator and staff at each participat-
ing site remained blinded to the timing of its randomly al-
located ‘step’ until 2 months before the month allocated
for each site’s PRIME intervention, when this had to be re-
vealed in order to organise the recruitment review.
The PRIME intervention
Two months before the allocated month of the recruit-
ment review, the recruitment co-ordinator sent an email to
RESTARTcollaborators at the site requesting that they pro-
vide suitable dates for their recruitment review teleconfer-
ence, which would be held with the PI and the RESTART
co-ordinator at the site (Additional file 2: Figure S2). Once
a date is agreed upon, the RESTART site co-ordinator is
sent a calendar invitation containing the dial-in details for
the teleconference and a questionnaire to be com-
pleted before the review enquiring about (a) the main
barriers preventing recruitment to RESTART, (b) what
sources are used to identify potential participants and (c)
what methods have been used to boost recruitment to
RESTART (Additional file 3). One or two days before the
recruitment review, a reminder of the dial-in details is
sent, and if the pre-review questionnaire has not yet been
completed and returned, it is re-sent with a further
request to complete it before the recruitment review.
Before the recruitment review, the recruitment co-
ordinator records basic details about the site receiving the
review, including (a) how long the site has been active; (b)
how many patients have been recruited there; (c) whether
they are part of the RESTART magnetic resonance imaging
sub-study, and, if so, how many patients they have recruited
into it; and (d) how many patients per year the site predicts
they would recruit at their site initiation visit.
Recruitment review
The recruitment review consists of the following:
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 Confirmation that all the relevant staff are present
 Review of RESTART delegation log to ensure it is
up to date
 Discussion on how staff at the site have been finding
RESTART
 Review of the recruitment commitment made at the
site initiation visit and how many patients have been
recruited
 Review of the data in the questionnaire about
recruitment completed before the recruitment
review
 Explanation of the availability of bespoke stroke
audit data exports and examples provided of how
the pilot sites effectively used them
 Review of the use of a template invitation letter for
approaching prevalent patients and discussion about
how they can be used effectively in conjunction with
the bespoke stroke audit data exports
 Review of the opportunities to recruit inpatients and
outpatients at the hospital site
 Sharing of what other methods top recruiting sites
have been using to identify, consent and randomise
patients
 Sharing any other relevant information about
recruitment (e.g., presentations available on the
RESTART website, collaborators meetings and
poster presentations at conferences, telephone
conferences with site staff )
 Confirmation that the site agrees to have a follow-
up review in 6 months to review progress after the
recruitment review
After the review, an email is sent to all the collabora-
tors at the site, summarising what was discussed at the
review, providing attendance certificates and giving in-
structions for running the relevant bespoke stroke audit
data exports
Bespoke stroke audit data exports
The data sources used in PRIME, alongside other local
hospital databases, are the Scottish Stroke Care Audit
(SSCA; http://www.strokeaudit.scot.nhs.uk/) and the Sen-
tinel Stoke National Audit Programme (SSNAP; https://
www.strokeaudit.org/Home.aspx). The SSCA was estab-
lished in 2002 and includes all hospitals managing acute
stroke in every Scottish NHS board, each of which uses
the SSCA to evaluate its stroke care against national stan-
dards and to drive improvements; inpatient and outpatient
data since January 2010 are available. The SSNAP has pro-
spectively collected a minimum dataset for stroke patients
in England and Wales since January 2013 to measure pro-
cesses of acute care, rehabilitation, care in the community,
and outcome measures at 6 months; inpatient data since
January 2013 are available. Bespoke stroke audit data
exports were created for PRIME in collaboration with the
SSCA and SSNAP teams to reflect the RESTART eligibil-
ity criteria as best the routinely collected data can. The ex-
ports show hospital staff, who have access to stroke audit
data, details about only their own hospital’s patients who
might be eligible for RESTART. These data can be shared
with local staff at each site on the RESTART delegation
log who are authorised to also view information about
patients within the clinical stroke service, with reference
to local information governance procedures. Because the
data will be exported locally, there will be no passage of
identifiable, patient-level data to a third party such as the
central RESTART trial co-ordinating team in Edinburgh.
A set of instructions (Additional files 4 and 5) is provided
to sites after their recruitment review, explaining how to
produce the bespoke stroke audit data exports. The local
research teams are responsible for validating the exported
information, confirming any patient’s potential eligibility
and contacting them to invite them to participate in RE-
START using one of the template letters of invitation.
Six-month follow-up review
Two months before the 6-month follow-up review is due,
an email is sent to determine availability. Once a date is
agreed upon, the site is sent a questionnaire to be com-
pleted before the review, along with a calendar invitation
containing the dial-in details for the teleconference. The
questionnaire enquires about (a) whether they have run the
bespoke stroke audit data exports since the recruitment re-
view; (b) if so, how many of the patients identified were eli-
gible; (c) how many eligible patients were recruited; and (d)
whether the exports were useful (Additional files 6 and 7).
One or two days before the follow-up review, a reminder of
the dial-in details is sent, and if the questionnaire has not
yet been completed and returned, it is re-sent with a further
request to complete it before the review. The follow-up
review consists of the following:
 A review of the use of the training given at the
initial recruitment review
 A review of the yield of the bespoke stroke audit
data exports
 Further recruitment tips not already provided at the
initial recruitment review
Comparator
All sites begin in a control state before receiving their
recruitment review (Additional file 1: Figure S1). The
control state period will vary from 6 to 17 months,
depending on the month in which the site receives the
recruitment review (i.e., the first component of the
intervention). No recruitment review or any other inter-
vention will be given to the sites during the control period.
The control period will be used as a comparator for the
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analysis against the intervention period (which is 6–17
months after the site receives their initial recruitment
review).
Study outcomes
The primary outcome is the total number of patients
randomised into RESTART per month per site. The RE-
START trial database collects information about every
randomisation in real time. The total number of people
randomised per month will be quantified at each site for
analysis. In PRIME, we will quantify the primary outcome
at each site in the comparator period before the recruit-
ment review occurs at that site, and we will measure the
primary outcome in the intervention period after the re-
cruitment review (Additional file 1: Figure S1). The time
periods analysed are likely to be sufficient to allow enough
time for the intervention to lead to recruitment of partici-
pants, and for us to be able to detect whether there is an
initial surge in recruitment as a result of the recruitment
review followed by a decay in the randomisation rate over
time.
We will collect data on secondary outcomes from the
information supplied in the questionnaires completed
before, at and 6 months after the recruitment review to
address the following subsidiary research questions:
a. Number of sites in PRIME that routinely used stroke
databases to identify potentially eligible patients
before receiving the recruitment review
b. Number of sites in PRIME that used the bespoke
stroke audit data exports, and the frequency of their
use in the 6 months after the recruitment review
c. Barriers to recruitment in PRIME, identified by sites
in the questionnaires completed before, at and 6
months after the recruitment review
d. Barriers to using the bespoke stroke audit data
exports identified by PRIME sites at the 6-month
follow-up review
e. Disadvantages of the bespoke stroke audit exports
identified by PRIME sites at the 6-month follow-up
review
Statistical methods
We modelled our predicted recruitment to PRIME using
live data from RESTART in March 2014 [15], when the rate
of randomisation was 0.28 participants per site per month
on average. RESTART recruitment data indicated that the
standard deviation of the paired difference in rates within
site before and after implementation of the intervention
would be 0.75 (assuming the pessimistic scenario of inde-
pendence between pre- and post-intervention rates within
sites). Therefore, 72 sites would give 87% power to detect a
change in rate of 0.28 participants per site per month
(paired t test, two-sided 5% significance level). This would
be consistent with the effect size that was seen in a previous
before-and-after study in which researchers found that an
electronic medical record-generated physician alert doubled
the recruitment rate into an RCT [16].
This protocol and the statistical analysis plan will be sub-
mitted for publication before all sites receive the PRIME
intervention and before outcome data are known. The stat-
istical analysis plan will be published separately from this
protocol. In brief, PRIME’s primary outcome of recruitment
rate per site per month will be compared before and after
the allocated month for the recruitment review using a
negative binomial generalised linear mixed model, informed
by a published method to model recruitment [17]. The pri-
mary analysis will follow an ‘as-randomised’ principle,
which means that the data will be analysed according to the
allocated timing of the recruitment review rather than the
time that the recruitment review actually occurred. In
addition, for the primary analysis, all sites will be included,
regardless of any site withdrawals and/or compliance with
the PRIME trial procedures. There will be no formal in-
terim analyses or stopping rules for early termination, be-
cause PRIME is a trial of an intervention to manage the
performance of sites to fulfil their recruitment targets and
is not a trial on patients.
Patient and public involvement
We have sought the views of the patient reference group
for the Research to Understand Stroke due to Haemor-
rhage programme (www.RUSH.ed.ac.uk). No extra burden
for patients was foreseen, given that the stroke audit data
exports would be screened by each patient’s hospital team
before each patient’s clinician invited them to participate.
Attempting to recruit eligible, prevalent patients who had
been discharged from hospital, but who might benefit
from participation in RESTART, was seen to be a good
thing. The patients reviewed and approved the wording of
the letters that would be sent to invite prevalent patients
to participate.
Data protection
All PIs and study site staff involved with PRIME must
comply with the requirements of the Data Protection Act
1998 with regard to the collection, storage, processing and
disclosure of personal information, and all will uphold the
act’s core principles and be appropriately trained in good
clinical practice. Computers used to collate the data will
have limited access measures via usernames and passwords.
Roles and responsibilities
The day-to-day running of PRIME is conducted by
the recruitment co-ordinator, supported and overseen by
the RESTART trial manager and chief investigator. The
progress of PRIME is overseen by the team that designed
the trial (RASS, CJW, AR and MD) and is discussed at the
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main RESTART Trial Steering Committee meetings. There
is no data monitoring committee, because there is no pa-
tient participation in this trial. RESTART is jointly spon-
sored by NHS Lothian and the University of Edinburgh
(Academic and Clinical Central Office for Research and
Development; http://www.accord.ed.ac.uk/). The sponsor
and funder had no role in study design; collection, manage-
ment, analysis and interpretation of data; the writing of this
report; or the decision to submit the report for publication.
The sponsor and funder will not have ultimate authority
over any of these activities.
Reporting
The trial will be reported in a manner consistent with
the adaptation of the Consolidated Standards of Report-
ing Trials (CONSORT) reporting guidelines for cluster
randomised trials [18], the guidelines for reporting
embedded recruitment trials [19], and the recommenda-
tions for reporting stepped-wedge trials proposed by
Hemming et al. [20] and Davey et al. [21]. The co-
authors of the protocol will submit the final report for
publication in a scientific journal and presentation at
relevant conferences. Published results will not contain
any personal data that could allow identification of
individual participants.
Discussion
PRIME is just one study within a trial (SWAT) amongst
many others (http://www.methodologyhubs.mrc.ac.uk/re-
sources/swat and http://www.qub.ac.uk/sites/TheNorther-
nIrelandNetworkforTrialsMethodologyResearch/SWATS-
WARInformation/) that are all attempting to improve the
evidence base to optimise recruitment and retention in
RCTs (e.g., http://www.trialforge.org/ and http://www.
orrca.org.uk/). PRIME differs from many of these studies
by using a cluster randomised design of an intervention at
the site level rather than an intervention at the patient
level, and using a stepped-wedge design to ensure that all
sites receive the intervention in view of the investigators’
concern to ensure that all sites have the opportunity to
boost their recruitment for the benefit of the parent
RESTART trial.
PRIME encountered delays when it was reviewed by the
study sponsor and the research ethics committee with
oversight of the RESTART (parent) trial, despite the opin-
ion that we obtained from the UK Health Research Author-
ity. If the evidence base for the most efficient ways to
conduct randomised trials is to be improved, regulatory
agencies should consider creating policies and guidance for
the review of methodological research embedded within
randomised trials in order to standardise processes and fa-
cilitate low-risk methodological research. In the meantime,
we recommend that future SWATs seek sponsor review
and research ethics committee approval as early as possible.
The results of PRIME may be generalisable to future
randomised trials of secondary prevention after stroke in
the United Kingdom that could use electronic data held
to identify potentially eligible participants. Results are
expected to be analysed in 2017 and then published.
Trial registration
The PRIME study is registered with the Northern Ireland
Hub for Trials Methodology Research SWAT repository
(SWAT22; http://bit.ly/2a4n7Yb) and was submitted to
the Online Resource for Recruitment research in Clinical
trials (ORRCA; http://www.orrca.org.uk/).
Trial status
The first recruitment review took place in September 2015,
and the last review in August 2016. The first 6-month
follow-up took place in March 2016, with the last one due
in February 2017.
Additional files
Additional file 1: Figure S1. PRIME stepped-wedge randomised trial
design. A schematic representation of the trial design. (PPTX 47 kb)
Additional file 2: Figure S2. Trial flowchart. Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) figure displaying
schedule of enrolment and interventions. (PPTX 43 kb)
Additional file 3: Pre-recruitment review questionnaire. (PDF 409 kb)
Additional file 4: SSNAP RESTART reporting instructions. (PDF 609 kb)
Additional file 5: SSCA RESTART reporting instructions. (PDF 788 kb)
Additional file 6: Six-month follow-up review questionnaire (for PRIME
sites using SSNAP). (PDF 396 kb)
Additional file 7: Six-month follow-up review questionnaire (for PRIME
sites using SSCA). (PDF 396 kb)
Abbreviations
CONSORT: Consolidated Standards of Reporting Trials; ICH: Intracerebral
haemorrhage; MRC: Medical Research Council; PI: Principal investigator;
PRIME: Promoting Recruitment using Information Management Efficiently;
RCT: Randomised controlled trial; RESTART: REstart or STop Antithrombotics
Randomised Trial; SPIRIT: Standard Protocol Items: Recommendations for
Interventional Trials; SSCA: Scottish Stroke Care Audit; SSNAP: Sentinel Stoke
National Audit Programme; SWAT: Study Within a Trial repository
Acknowledgements
We thank the Scottish Stroke Care Audit and the Sentinel Stroke National
Audit Programme for providing the data extraction tools and supporting
their implementation. We thank the RESTART collaborators who took part in
PRIME, as well as Jonathan Drever and Ronnie Harkness for their help with
PRIME. RAP and CJW were supported by NHS Lothian via the Edinburgh
Clinical Trials Unit, and RASS was supported by an MRC senior clinical
fellowship.
Funding
The British Heart Foundation funds PRIME (PG/14/50/30891) and RESTART
(SP/12/2/29422). RASS was funded by an MRC senior clinical fellowship.
Availability of data and materials
The datasets acquired and/or analysed during PRIME will be available from
the corresponding author on reasonable request after the publication of the
PRIME results.
Maxwell et al. Trials  (2017) 18:22 Page 6 of 7
Authors’ contributions
AEM designed, implemented and conducted the study, and also wrote the
first draft of the manuscript. MD conceived of the idea for the study and
obtained funding. AR conceived of the idea for the study and obtained
funding. CJW conceived of the idea for the study, obtained funding,
designed the study and will perform the statistical analysis. RAP designed
the study and will perform the statistical analysis. RASS conceived of the idea
for the study, obtained funding, designed and implemented the study, and
revised the manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
We obtained approval from the Scotland A Research Ethics Committee on
24 April 2015 (reference 12/SS/0138, amendment REC REF AM18/1) for two
template invitation letters for RESTART investigators to use in PRIME and
RESTART with which to approach potentially eligible prevalent patients,
identified using the bespoke data exports, and seen by their stroke service.
RESTART investigators opted in to participate in recruitment reviews. Written
informed consent was not required. The Health Research Authority’s view
was that ‘PRIME is research, but it does not require review by an NHS
research ethics committee’. Although we were concerned about the
possibility that knowledge of PRIME could confound sites’ performance, for
PRIME to proceed the sponsor and the research ethics committee required
the following information to be added to the RESTART protocol: ‘We will
also study trial methodology by performing an opt-in, cluster-randomised,
stepped wedge trial at a sub-group of RESTART sites, to assess the effects of
an intervention to manage the performance of sites to help them fulfil the
recruitment targets they set at their site initiation visit’.
Author details
1Centre for Clinical Brain Sciences, University of Edinburgh, Chancellor’s
Building, 49 Little France Crescent, Edinburgh EH16 4SB, UK. 2St Thomas’
Hospital, Westminster Bridge Road, London, UK. 3Edinburgh Clinical Trials
Unit and Centre for Population Health Sciences, Usher Institute of Population
Health Sciences and Informatics, Medical School, University of Edinburgh,
Teviot Place, Edinburgh, UK.
Received: 11 August 2016 Accepted: 10 November 2016
References
1. Tudur Smith C, Hickey H, Clarke M, Blazeby J, Williamson P. The trials
methodological research agenda: results from a priority setting exercise.
Trials. 2014;15:32.
2. Treweek S, Lockhart P, Pitkethly M, Cook JA, Kjeldstrøm M, Johansen M,
et al. Methods to improve recruitment to randomised controlled trials:
Cochrane systematic review and meta-analysis. BMJ Open. 2013;3:e002360.
3. Al-Shahi Salman R, Beller E, Kagan J, Hemminki E, Phillips RS, Savulescu J,
et al. Increasing value and reducing waste in biomedical research regulation
and management. Lancet. 2014;383:176–85.
4. Campbell MK, Snowdon C, Francis D, Elbourne D, McDonald AM, Knight R,
et al. Recruitment to randomised trials: strategies for trial enrollment and
participation study. The STEPS study. Health Technol Assess.
2007;11(48):iii. ix-105.
5. Sully BG, Julious SA, Nicholl J. A reinvestigation of recruitment to
randomised, controlled, multicenter trials: a review of trials funded by two
UK funding agencies. Trials. 2013;14:166.
6. Fonville AF, Samarasekera N, Hutchison A, Perry D, Roos YB, Al-Shahi SR.
Eligibility for randomized trials of treatments specifically for intracerebral
hemorrhage: community-based study. Stroke. 2013;44:2729–34.
7. McDonald AM, Knight RC, Campbell MK, Entwistle VA, Grant AM, Cook JA,
et al. What influences recruitment to randomised controlled trials? A review
of trials funded by two UK funding agencies. Trials. 2006;7:9.
8. Samarasekera N, Fonville A, Lerpiniere C, Farrall AJ, Wardlaw JM, White PM,
et al. Influence of intracerebral hemorrhage location on incidence,
characteristics, and outcome: population-based study. Stroke. 2015;46:361–8.
9. Watson JM, Torgerson DJ. Increasing recruitment to randomised trials:
a review of randomised controlled trials. BMC Med Res Methodol. 2006;6:34.
10. Fletcher B, Gheorghe A, Moore D, Wilson S, Damery S. Improving the
recruitment activity of clinicians in randomised controlled trials: a systematic
review. BMJ Open. 2012;2:e000496.
11. Staa TP, Goldacre B, Gulliford M, Cassell J, Pirmohamed M, Taweel A, et al.
Pragmatic randomised trials using routine electronic health records: putting
them to the test. BMJ. 2012;344:e55.
12. Treweek S, Pearson E, Smith N, Neville R, Sargeant P, Boswell B, et al.
Desktop software to identify patients eligible for recruitment into a clinical
trial: using SARMA to recruit to the ROAD feasibility trial. Inform Prim Care.
2010;18:51–8.
13. Brown CA, Lilford RJ. The stepped wedge trial design: a systematic review.
BMC Med Res Methodol. 2006;6:54.
14. Copas AJ, Lewis JJ, Thompson JA, Davey C, Baio G, Hargreaves JR.
Designing a stepped wedge trial: three main designs, carry-over effects and
randomisation approaches. Trials. 2015;16:352.
15. Barnard KD, Dent L, Cook A. A systematic review of models to predict
recruitment to multicentre clinical trials. BMC Med Res Methodol. 2010;10:
63.
16. Embi PJ, Jain A, Clark J, Bizjack S, Hornung R, Harris CM. Effect of a clinical
trial alert system on physician participation in trial recruitment. Arch Intern
Med. 2005;165:2272–7.
17. Anisimov VV, Fedorov VV. Modelling, prediction and adaptive adjustment of
recruitment in multicentre trials. Stat Med. 2007;26:4958–75.
18. Campbell MK, Piaggio G, Elbourne DR, Altman DG, CONSORT Group.
Consort 2010 statement: extension to cluster randomised trials. BMJ.
2012;345:e5661.
19. Madurasinghe VW, Eldridge S, Forbes G. Guidelines for reporting embedded
recruitment trials. Trials. 2016;17:27.
20. Hemming K, Haines TP, Chilton PJ, Girling AJ, Lilford RJ. The stepped wedge
cluster randomised trial: rationale, design, analysis, and reporting. BMJ.
2015;350:h391.
21. Davey C, Hargreaves J, Thompson JA, Copas AJ, Beard E, Lewis JJ, et al.
Analysis and reporting of stepped wedge randomised controlled trials:
synthesis and critical appraisal of published studies, 2010 to 2014. Trials.
2015;16:358.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Maxwell et al. Trials  (2017) 18:22 Page 7 of 7
